| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | — | — |
| Sell | — | — | — | — | — | — | — | — | — | — | — | — |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 4.60 | 2.83 | 11.03 | 8.11 |
| Receivables | 0.01 | — | — | — |
| Inventory | — | — | — | — |
| Other | — | — | — | — |
| 4.86 | 2.89 | 11.06 | 8.17 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 0.54 | 0.72 | 0.13 | 0.04 |
| ST’ Debt | — | — | — | — |
| Other | — | — | — | — |
| 0.56 | 0.72 | 0.70 | 0.04 |
| 10y | 5y | 3y | |
| Sales | — | — | — |
| Cash Flow | — | ‡‡‡ | ‡‡‡ |
| Earnings | — | ‡‡‡ | ‡‡‡ |
| Book Value | — | ‡‡‡ | ‡‡‡ |
| Year |
|---|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (1.20) | (1.21) | — | — |
—
|
| ’25 | (1.63) | (0.80) | (1.10) | (1.14) |
(4.66)
|
| ’24 | (1.05) | (0.86) | (1.84) | (1.80) |
(5.56)
|
| ’23 | (1.08) | (0.66) | (1.76) | (1.03) |
(4.53)
|
| ’22 | — | (3.31) | (1.31) | (0.98) |
(5.60)
|
| ’21 | — | — | — | — |
(1.38)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (1.20) | (1.21) | — | — |
—
|
| ’25 | (1.63) | (0.80) | (1.10) | (1.14) |
(4.66)
|
| ’24 | (1.05) | (0.86) | (1.84) | (1.80) |
(5.56)
|
| ’23 | (1.08) | (0.66) | (1.76) | (1.03) |
(4.53)
|
| ’22 | — | (3.31) | (1.31) | (0.98) |
(5.60)
|
| ’21 | — | — | — | — |
(1.38)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (0.03) | (0.03) | — | — |
—
|
| ’25 | (0.11) | (0.09) | (1.18) | — |
(1.35)
|
| ’24 | (0.12) | (0.11) | (0.14) | (0.15) |
(0.51)
|
| ’23 | (0.09) | (0.10) | (0.26) | (0.19) |
(0.64)
|
| ’22 | — | (0.16) | (0.12) | — |
(0.48)
|
| ’21 | — | — | — | — |
(0.15)
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | 0.92 | 0.51 | 0.73 | — | — | — |
Low Price
|
| — | — | — | — | — | — | — | 7.98 | 5.01 | 2.45 | — | — | — |
High Price
|
| — | — | — | — | — | — | 6 | 3 | 5 | 2 | — | — | — |
Employees
|
| — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue/Emp
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡‡‡ | — | — |
Revenue
|
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Gross Margin
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | (7.06) | (11.98) | (7.85) | (10.44) | — | — | — |
EBT
|
| — | — | — | — | ‡‡‡ | ‡‡‡ | 0.00% | 0.00% | 0.00% | 0.00% | ‡‡‡ | ‡‡‡ | ‡‡‡ |
EBT Margin
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | (7.06) | (11.98) | (7.85) | (10.44) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Net Income
|
| — | — | — | — | — | — | — | 0.73 | — | — | — | — | — |
Depreciation
|
| — | — | — | — | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Revenue/Sh
|
| — | — | — | — | ‡‡‡ | ‡‡‡‡‡ | (0.48) | (0.64) | (0.51) | (1.35) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Earnings/Sh
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.32) | (0.33) | (0.36) | (0.20) | — | — | — |
Cash Flow/Sh
|
| — | — | — | — | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Capex/Sh
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.32) | (0.33) | (0.36) | (0.20) | — | — | — |
Free CF/Sh
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.03) | 0.31 | 0.14 | 0.44 | — | — | — |
Book Value/Sh
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 17.57 | 13.92 | 15.44 | 23.69 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Shares
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
PE Ratio
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PS Ratio
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PB Ratio
|
| — | — | — | — | — | — | — | — | — | — | ‡‡‡‡ | — | — |
EV/Sales
|
| — | — | — | — | — | — | — | — | — | — | — | — | — |
EV/FCF
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | (5.60) | (4.53) | (5.56) | (4.66) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Op' Cash Flow
|
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Capex
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | (5.60) | (4.53) | (5.56) | (4.66) | ‡‡‡‡‡ | — | — |
FCF
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.88) | 4.30 | 2.16 | 10.36 | — | — | — |
Working Cap'
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.22 | — | — | — | — | — | — |
Total Debt
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.13) | (4.60) | (2.83) | (11.03) | — | — | — |
Net Debt
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.60) | 4.37 | 2.20 | 10.39 | — | — | — |
Sh' Equity
|
| — | — | — | — | ‡‡‡ | ‡‡‡‡‡ | (335.04%) | (413.86%) | (199.93%) | (456.59%) | — | — | — |
ROA
|
| — | — | — | — | ‡‡‡ | ‡‡‡ | 0.00% | 0.00% | 0.00% | 0.00% | — | — | — |
ROIC
|
| — | — | — | — | ‡‡‡ | ‡‡‡‡‡ | (847.73%) | (634.30%) | (238.90%) | (508.28%) | — | — | — |
ROE
|
MIRA Pharmaceuticals, a lean clinical-stage biopharma with just 3-6 employees, exemplifies small-cap biotech risks amid high interest rates and funding droughts since 2022. Pre-revenue and burning cash aggressively, losses ballooned from -$68,000 in 2020 to -$11.98 million in 2023 before easing 34% to -$7.85 million in 2024, driven by R&D in novel oral ketamine analogs for neurology amid the opioid crisis aftermath. Trading 60% below consensus targets after volatile swings tied to trial hype and sector slumps, the stock signals 159% upside potential if Phase 2/3 milestones deliver.
The balance sheet offers resilience with cash reserves exceeding debt, working capital at $2.16 million, and improving ROE, buffering Fed rate hikes that starved peers. Cash burn worsened to -$5.56 million in operating outflows, but analysts forecast a dramatic inflection: revenue exploding to $276 million in 2025-2026 from zero, FCF surging to $398 million by 2026, and EV/sales at a bargain 0.06x—though dilution from 185% share growth and regulatory delays loom.
In a macro thaw with biotech discounts at 40% to norms, geopolitical ripples like U.S.-China trade frictions and mental health surges (25% global rise post-COVID) could propel MIRA’s CNS disruptors. Yet insider silence and binary trial risks underscore high-stakes volatility—delve deeper for the full dissection of this potential multi-bagger poised on 2026 catalysts.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.